Taurina, a vaccine industry expert who served at the Centers for Disease Control and Prevention in Shanghai for 15 years, said in an interview with Time Financial on Jan. \"
Recently, the state drug administration issued an announcement that approved xiamen wantai sea biotechnology co., ltd.(hereinafter referred to as \"wantai company \") dual-valent human papillomavirus vaccine (escherichia coli)(trade name: xin koning) market injection application.
The vaccine, the first domestic cervical cancer vaccine to be converted by wantai, a joint venture between wantai and xiamen university, means china's history of having to rely only on imports.
At present, cervical cancer has become the third most common cancer among women in the world. With the increasing popularity of cervical cancer prevention awareness, the demand for cervical cancer vaccine is increasing, and the global demand is up to 100 million a year. But with limited technology and fewer companies producing cervical cancer vaccines, the global supply capacity is now just 30 million, less than a third of total demand. Almost 600,000 new cases are reported worldwide each year, with more than 300,000 women dying from the disease each year. In China, the number of new cases of cervical cancer is about 150,000 a year, and the number of deaths is about 10,000, accounting for about% of all deaths from malignant tumors in women.
At present, about 400 million people in China need to be vaccinated against HPV. Time Finance combed the statistics of the China Institute of Food and Drug Control and Research found that in 2018, the number of domestic HPV issuance was 7 million, and in 2019 it was close to 9 million. At present, the supply of 3 injections per person is far from meeting the needs of the domestic market, resulting in a hard-to-find, rocking situation.
Before the approval of the Wantai HPV vaccine, there were three global HPV vaccines, the two-valent vaccine for HPV16 and 18 produced by GlaxoSmithKline, the four-valent vaccine for HPV6,11,16,18 and the nine-valent vaccine for HPV6,11,16,18,31,33,45,52 and 58.
Among them, the bivalent HPV vaccine protects against two high-risk HPV viruses (HPV-16 and HPV-18), and more than 80% of cervical cancer in the Chinese population is caused by these two viruses.
In theory, the prevention rate of bivalent and tetravalent vaccines is 84 percent, and the nine-valent vaccine prevention rate is 92 percent, said Taurina, a vaccine industry expert who served at the Centers for Disease Control and Prevention in Shanghai for 15 years in an interview with Time Finance on Jan. \"Although it is widely accepted that the nine-valent vaccine is much better than bivalent and tetravalent in preventing cervical cancer, there is evidence that the three are not significantly different in practical terms.
In addition, Zhang Jun, vice president of Xiamen University's School of Public Health, said in a media interview that the approved double-valent human papillomavirus vaccine used an E. coli production system, which is less costly and more conducive to the expansion of future production capacity, compared with GlaxoSmithKline's two-valent HPV vaccine using insect cell production systems and the recombinant Saccharomyces cerevisiae production system used by Mercadon.
Time Finance noted that the current import of HPV vaccine prices are generally high. According to the price announced by the CDC in Beijing, the imported nine-valent vaccine is 1298 yuan (RMB)\/pin, and the full cost is about 4000 yuan. The imported bivalent vaccine is 580 yuan \/ needle, and the whole process also needs nearly 2000 yuan.
According to the company's information, its HPV vaccine is priced at 329 yuan \/ needle,9-14 years of age group full 658 yuan, older group full 987 yuan. The price is about half the price of imported bivalent vaccines.
Despite tao lina's belief that the domestic listing of bivalent cervical cancer vaccine is a \"landmark \", he said that if purely technical, the domestic vaccine\" can only be counted as moderate, and there is no special bright spot.\"
GlaxoSmithKline's bivalent HPV vaccine uses a new adjuvant technology that has won a Nobel Prize for its principles and produces higher antibodies against two high-risk HPV viruses (HPV-16 and HPV-18), it said. Tao believes that the current domestic vaccine compared to imported vaccines,\" does not have a key advantage.\"
The key, he says, is how companies promote the vaccine in the domestic market. In his view, the promotion of this domestic vaccine in first-tier cities is more difficult, on the one hand, the imported vaccine, domestic vaccine has only a price advantage competitiveness is not enough; on the other hand, the first-tier cities generally know more about cervical cancer vaccine, and the nine-valent vaccine is more recognized.
But he argues that second- and third-tier cities will be more receptive to home-made vaccines than first-tier cities,\" if some regional government procurement policies can be achieved, then the high probability of home-made vaccines will be a priority for the government.\"
The latest study found that a single dose of cervical cancer vaccine could be used to prevent the disease. In the case of fewer injections and lower prices, the probability of achieving free vaccination for adolescents in China will be further increased. Industry insiders believe it is only a matter of time before a vaccine for cervical cancer is given free of charge in china, in a context where many developed countries have included it.
Time notes that on September 9,2019, Wantai has signed a cooperation agreement with GlaxoSmithKline to jointly develop a new generation of human papillomavirus vaccine based on Wantai's innovative antigen technology with Glaxo's adjuvant system.